CONTRIBUTORS

Peripheral Nerve and Motor Neuron Disorders p. 1122-1126 October 2020, Vol.26, No.5 doi: 10.1212/01.CON.0000718692.81934.43
CONTRIBUTORS
BROWSE ARTICLES

A. Gordon Smith, MD, FAAN Guest Editor

Professor and Chair of Neurology, Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research (Neurology), Virginia Commonwealth University, Richmond, Virginia

Relationship Disclosure: Dr Smith serves as a consultant for Alexion Pharmaceuticals, Inc; Argenx; Disarm Therapeutics; Eidos Therapeutics; and Regenesis Biomedical, Inc. Dr Smith receives research/grant support from the National Institutes of Health (U01NS095388, R01DK064814).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Smith reports no disclosure.

Ted M. Burns, MD

Harrison Distinguished Professor of Neurology, University of Virginia, Charlottesville, Virginia

Relationship Disclosure: Dr Burns reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Burns reports no disclosure.

Brian C. Callaghan, MD, MS, FAAN

Associate Professor of Neurology, University of Michigan, Ann Arbor, Michigan

Relationship Disclosure: Dr Callaghan serves on a scientific advisory board for a Patient-Centered Outcomes Research Institute grant, on the International Diabetes Neuropathy Consortium board for the Peripheral Nerve Society, on the editorial board of Neurology, and as a consultant for DynaMed. Dr Callaghan has received research/grant support from the American Academy of Neurology, JDRF, the National Institutes of Health (R01 DK115687), and the US Department of Veterans Affairs (Clinical Science Research and Development Merit I01CX001504) and provided consulting services for medicolegal cases and the US Vaccine Injury Compensation Program.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Callaghan reports no disclosure.

Jason L. Crowell, MD

Neurologist, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Jerome H. Grossman MD Graduate Fellow, Harvard Kennedy School, Cambridge, Massachusetts

Relationship Disclosure: Dr Crowell has received fellowship support from Medtronic.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Crowell reports no disclosure.

Lauren Elman, MD

Associate Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Elman serves on advisory boards for Biogen and Genentech, Inc, and receives publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Elman discusses the unlabeled/investigational use of anticholinergics, clonazepam, levetiracetam, mexiletine, mirtazapine, phenytoin, selective serotonin reuptake inhibitors, steroids, and tricyclic antidepressants for the treatment of amyotrophic lateral sclerosis and other motor neuron diseases.

Christopher H. Gibbons, MD, MMSc, FAAN

Associate Professor of Neurology, Harvard Medical School, Boston, Massachusetts

Relationship Disclosure: Dr Gibbons has received personal compensation for serving as a scientific advisor for Lundbeck and Theravance Biopharma and as an associate editor for Autonomic Neuroscience: Basic and Clinical, research/grant support from Grifols, and publishing royalties from UpToDate, Inc. Dr Gibbons has held stock/stock options in Cutaneous Neurodiagnostics, LLC, and has given expert medical testimony.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gibbons reports no disclosure.

Kelly Gwathmey, MD

Assistant Professor of Neurology; Chief, Division of Neuromuscular Medicine, Virginia Commonwealth University, Richmond, Virginia

Relationship Disclosure: Dr Gwathmey has served as a consultant for and received personal compensation for speaking engagements from Alexion Pharmaceuticals, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gwathmey discusses the unlabeled/investigational use of azathioprine, bortezomib, corticosteroids (methylprednisolone, prednisone), cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, and rituximab for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy and its variants.

Chafic Karam, MD

Associate Professor, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Karam has served as a deputy editor for Neurology and as a consultant for Acceleron Pharma, Inc; Akcea Therapeutics; Alnylam Pharmaceuticals, Inc; Argenx; Biogen; CSL Behring; and Sanofi Genzyme. Dr Karam has received personal compensation for speaking engagements from Akcea Therapeutics; Alnylam Pharmaceuticals, Inc; CSL Behring; and Sanofi Genzyme and research/grant support from Akcea Therapeutics and Sanofi Genzyme.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Karam discusses the unlabeled/investigational use of cyclophosphamide, immunoglobulin, rituximab, and steroids in the treatment of vasculitis and immune-mediated neuropathy in rheumatologic disorders.

Christopher J. Klein, MD, FAAN

Professor of Neurology, Mayo Clinic, Rochester, Minnesota

Relationship Disclosure: Dr Klein serves on the clinical expert and therapy boards of the Charcot-Marie-Tooth Association. Dr Klein has received personal compensation for speaking engagements at the Neuropathic Pain Symposium and research/grant support from the Mayo Clinic Center for Individualized Medicine.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Klein reports no disclosure.

Zachary N. London, MD, FAAN

James W. Albers Collegiate Professor of Neurology and Clinical Professor of Neurology, University of Michigan Medical School, Ann Arbor, Michigan

Relationship Disclosure: Dr London has received personal compensation for speaking engagements from the American Academy of Neurology, the American Association of Neuromuscular & Electrodiagnostic Medicine, the American Clinical Neurophysiology Society, the University of Pennsylvania, and the University of Rochester.

Unlabeled Use of Products/Investigational Use Disclosure: Dr London reports no disclosure.

Michelle L. Mauermann, MD, FAAN

Professor of Neurology, Neuromuscular Division of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Relationship Disclosure: Dr Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives research/grant support from Alnylam Pharmaceuticals, Inc, and Ionis Pharmaceuticals, Inc; and receives publishing royalties from Oxford University Press.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Mauermann discusses the unlabeled/investigational use of IV immunoglobulin and rituximab for the treatment of IgM neuropathy.

Elie Naddaf, MD

Assistant Professor of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Relationship Disclosure: Dr Naddaf reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Naddaf discusses the unlabeled/investigational use of IV immunoglobulin and rituximab for the treatment of IgM neuropathy.

Jessica Rose Nance, MD

Assistant Professor of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Relationship Disclosure: Dr Nance receives research/grant support from AveXis, Inc; Biogen; Catabasis Pharmaceuticals, Inc; Catalyst Pharmaceuticals, Inc; Cytokinetics, Inc; Santhera Pharmaceuticals; and Scholar Rock.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Nance reports no disclosure.

Amanda C. Peltier, MD, MS

Associate Professor of Neurology; Associate Professor of Medicine, Director of Cardiology, Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee

Relationship Disclosure: Dr Peltier serves as secretary of the International Diabetes Neuropathy Consortium, on the board of directors of the American Autonomic Society, and on advisory boards for Akcea Therapeutics; Alnylam Pharmaceuticals, Inc; and CSL Behring. Dr Peltier has received personal compensation for speaking engagements from Akcea Therapeutics and CSL Behring and research/grant support from Akcea Therapeutics, CSL Behring, and the National Institute of Neurological Disorders and Stroke NeuroNEXT.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Peltier discusses the unlabeled/investigational use of a-lipoic acid, amitriptyline, cannabidiol oil, carbamazepine, nortriptyline, oxcarbazepine, spinal cord stimulators, valproic acid, and venlafaxine for the treatment of neuropathic pain in polyneuropathy.

Colin Quinn, MD

Assistant Professor of Clinical Neurology, University of Pennsylvania, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Quinn serves on advisory boards for Acceleron Pharma, Inc, and Amylyx Pharmaceuticals and as a consultant for Amicus Therapeutics, Inc. Dr Quinn receives research/grant support from Acceleron Pharma, Inc; Amicus Therapeutics, Inc; and Amylyx Pharmaceuticals.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Quinn discusses the unlabeled/investigational use of anticholinergics, clonazepam, levetiracetam, mexiletine, mirtazapine, phenytoin, selective serotonin reuptake inhibitors, steroids, and tricyclic antidepressants for the treatment of amyotrophic lateral sclerosis and other motor neuron diseases.

Kazim A. Sheikh, MBBS

Professor of Neurology, McGovern Medical School, University of Texas; Director, Neuromuscular Program, Houston Health Science Center, Houston, Texas

Relationship Disclosure: Dr Sheikh serves on the medical advisory board of the GBS/CIDP Foundation International and on the editorial board of Scientific Reports. Dr Sheikh has received personal compensation for speaking engagements from CSL Behring and research/grant support from the Department of Defense (W81XWH-18-1-0422) and the National Institute of Neurological Disorders and Stroke (R21NS107961).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Sheikh reports no disclosure.

Nathan P. Staff, MD, PhD, FAAN

Associate Professor and Consultant of Neurology, Mayo Clinic, Rochester, Minnesota

Relationship Disclosure: Dr Staff serves as an associate editor of Stem Cell Research & Therapy and receives research/grant support from BrainStorm Cell Limited; Disarm Therapeutics; the National Institutes of Health (R01 CA211887); Orion Therapeutics, LLC; and Regenerative Medicine Minnesota (RMM 11215 CT002).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Staff reports no disclosure.

Derek Wood, MD

Neurologist, UW Medicine–Valley Medical Center, Renton, Washington

Relationship Disclosure: Dr Wood reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Wood discusses the unlabeled/investigational use of a-lipoic acid, amitriptyline, cannabidiol oil, carbamazepine, nortriptyline, oxcarbazepine, spinal cord stimulators, valproic acid, and venlafaxine for the treatment of neuropathic pain in polyneuropathy.

Self-Assessment and CME Test Writers

Douglas J. Gelb, MD, PhD, FAAN

Professor of Neurology, University of Michigan, Ann Arbor, Michigan

Relationship Disclosure: Dr Gelb receives royalties from MedLink, Oxford University Press, and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gelb reports no disclosure.

D. Joanne Lynn, MD, FAAN

Associate Dean for Student Life, Clinical Professor of Neurology, The Ohio State University College of Medicine, Columbus, Ohio

Relationship Disclosure: Dr Lynn receives book royalties from Lippincott Williams & Wilkins and holds stock in Abbott Laboratories; AbbVie Inc; Amgen Inc; Bristol-Myers Squibb Company; CVS Health Corporation; Express Scripts Holding Company; General Electric; Merck & Co, Inc; and Zimmer Biomet.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Lynn reports no disclosure.

© 2020 American Academy of Neurology.